Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D. - 2Verdicts against social media companies carry consequences. But questions linger
- 3Passover under fire: Israelis balance fatigue with cautious hope after month of war
- 4Flu season is just beginning, but doctors are already on high alert
- 5Favored Organic product for Seniors' Prosperity: Make Your Determination
- Smooth countdown continues for Artemis II moon mission
- How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
- Barn Stored Lotus Esprit Turbo Seen After 30 Years
- One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Michael Jordan donates $10M to North Carolina medical center in honor of his mother
- Top 20 Compelling Business Books for Progress
- 6 Solid Moving Administrations for a Calm Movement
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
